Cerenome（CNSY）株式概要
臨床段階の製薬企業であるCerenome, Inc.は、がん患者向けの治療法の開発、製造、および商業化に注力しています。 詳細
CNSY Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cerenome, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$1.90 |
| 52週高値 | US$23.43 |
| 52週安値 | US$1.90 |
| ベータ | 1.39 |
| 1ヶ月の変化 | -38.11% |
| 3ヶ月変化 | -53.43% |
| 1年変化 | -82.05% |
| 3年間の変化 | -93.92% |
| 5年間の変化 | -99.73% |
| IPOからの変化 | -99.90% |
最新ニュース
ナラティブ更新 • Sep 11
CNSY: CNS Delivery Platform And CSF Assay Expansion Will Drive Future Upside
Analysts have reset their price target for Cerenome from $38.00 to $32.50, reflecting updated assumptions on higher projected revenue growth, wider profit margins, a slightly higher discount rate, and a lower future P/E multiple. What’s in the News for Cerenome Cerenome plans a private placement of senior secured convertible notes with 3i, LP with an aggregate original principal amount of US$21,276,596 at a 6% original issue discount, for expected proceeds of about US$20,000,000.24.
ナラティブ更新 • Jul 06
PSTV: CNSide Coverage And Rebranding Will Reprice Future CNS Oncology Shares
Analysts have trimmed their 12 month price target on Plus Therapeutics to $57 from $65, citing updated fair value assumptions, a modestly higher discount rate, and revised estimates for future revenue growth, profit margins, and P/E multiples. What’s in the News for Plus Therapeutics Plus Therapeutics announced a corporate rebranding to Cerenome, with its Nasdaq ticker expected to change from PSTV to CNSY effective August 3, 2026, according to its mid year business update.
ナラティブ更新 • Jun 22
PSTV: CNS Oncology Pipeline And New CPT Code Will Drive Upside
Analysts have adjusted their fair value estimate for Plus Therapeutics stock from $1 to $12, citing updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple as key drivers of the new price target framework. Analyst Commentary Recent Street research on Plus Therapeutics signals a more cautious tone, with bearish analysts revisiting their assumptions around valuation, execution risk and the pace at which the company may be able to translate its pipeline into financial results.ナラティブ更新 • Jun 08
PSTV: Future CNS Oncology CPT Codes Will Reprice Shares Despite Downgrades
Analysts have reduced their price target on Plus Therapeutics by $25.50, reflecting updated views on the company’s growth prospects and risk profile following recent research revisions from the Street. Analyst Commentary Recent Street research on Plus Therapeutics highlights a mix of caution and potential upside, with price targets and ratings being recalibrated to reflect updated views on execution risk and commercialization timelines.Recent updates
ナラティブ更新 • Sep 11
CNSY: CNS Delivery Platform And CSF Assay Expansion Will Drive Future Upside
Analysts have reset their price target for Cerenome from $38.00 to $32.50, reflecting updated assumptions on higher projected revenue growth, wider profit margins, a slightly higher discount rate, and a lower future P/E multiple. What’s in the News for Cerenome Cerenome plans a private placement of senior secured convertible notes with 3i, LP with an aggregate original principal amount of US$21,276,596 at a 6% original issue discount, for expected proceeds of about US$20,000,000.24.ナラティブ更新 • Jul 06
PSTV: CNSide Coverage And Rebranding Will Reprice Future CNS Oncology Shares
Analysts have trimmed their 12 month price target on Plus Therapeutics to $57 from $65, citing updated fair value assumptions, a modestly higher discount rate, and revised estimates for future revenue growth, profit margins, and P/E multiples. What’s in the News for Plus Therapeutics Plus Therapeutics announced a corporate rebranding to Cerenome, with its Nasdaq ticker expected to change from PSTV to CNSY effective August 3, 2026, according to its mid year business update.ナラティブ更新 • Jun 22
PSTV: CNS Oncology Pipeline And New CPT Code Will Drive Upside
Analysts have adjusted their fair value estimate for Plus Therapeutics stock from $1 to $12, citing updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple as key drivers of the new price target framework. Analyst Commentary Recent Street research on Plus Therapeutics signals a more cautious tone, with bearish analysts revisiting their assumptions around valuation, execution risk and the pace at which the company may be able to translate its pipeline into financial results.ナラティブ更新 • Jun 08
PSTV: Future CNS Oncology CPT Codes Will Reprice Shares Despite Downgrades
Analysts have reduced their price target on Plus Therapeutics by $25.50, reflecting updated views on the company’s growth prospects and risk profile following recent research revisions from the Street. Analyst Commentary Recent Street research on Plus Therapeutics highlights a mix of caution and potential upside, with price targets and ratings being recalibrated to reflect updated views on execution risk and commercialization timelines.ナラティブ更新 • May 24
PSTV: Future Brain Cancer CPT Codes Could Reprice Shares Despite Recent Downgrades
Analysts have cut their price target on Plus Therapeutics by $25.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples following recent downgrades and target revisions. Analyst Commentary Recent research notes highlight a shift in how analysts frame the risk and reward around Plus Therapeutics.ナラティブ更新 • May 02
PSTV: CNS Delivery And New CPT Codes Will Drive Future Upside
Analysts have adjusted their view on Plus Therapeutics, cutting the average price target by $25.50 while updating their models for fair value, discount rate, profit margin and future P/E to reflect a mix of rating changes and new coverage. Analyst Commentary Recent Street research on Plus Therapeutics reflects a mix of optimism about long term potential and caution around execution and valuation, with one firm initiating coverage positively and others resetting expectations through a downgrade and a lower price target.ナラティブ更新 • Apr 18
PSTV: Future Brain Cancer CPT Codes And Delivery Technique Could Reprice Shares
Narrative Update The updated analyst price target for Plus Therapeutics moves from about $475 to roughly $65, as analysts cite recent target cuts and a downgrade, along with one newer bullish initiation that together lead to a more tempered but still constructive set of assumptions on revenue growth, margins, and future P/E. Analyst Commentary Recent Street research on Plus Therapeutics shows a mix of caution and optimism, with several firms trimming targets and one newer, more constructive initiation helping to reset expectations rather than support extreme outcomes.ナラティブ更新 • Apr 03
PSTV: Future Brain Cancer CPT Code And FDA Dialogue Could Reprice Shares
The analyst price target for Plus Therapeutics has shifted from $20.50 to $475.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E. This change is informed by recent mixed Street research that includes a downgrade from D.ナラティブ更新 • Mar 20
PSTV: Upcoming CNS Milestones And New CPT Code Will Shape Upside Potential
Narrative Update on Plus Therapeutics Analysts have trimmed their price targets on Plus Therapeutics by about $1 to $1.50, reflecting revised views on profit margin potential and valuation, while still citing supportive research coverage for the story. Analyst Commentary Recent research updates paint a mixed picture for Plus Therapeutics, with one initiation taking a constructive stance and other reports trimming price targets by $1 to $1.50.ナラティブ更新 • Mar 06
PSTV: FDA Pivotal Trial Design And Brain Cancer Pipeline Will Drive Upside
Analysts have reduced their blended price target on Plus Therapeutics by about $0.60, reflecting updated views on fair value, revenue growth expectations, profit margins, and future P/E following recent initiations and target changes from several firms. Analyst Commentary Recent Street research on Plus Therapeutics shows a mix of views, with some firms starting coverage positively while others are taking a more conservative stance through reduced price targets.ナラティブ更新 • Feb 19
PSTV: Upcoming CNS Milestones And Diagnostics Rollout Will Drive Future Upside
Analysts have trimmed their average Plus Therapeutics price target by $2.50, citing updated assumptions around discount rates, profit margins and a higher future P/E multiple, while still maintaining their fair value estimate at $5.50. Analyst Commentary Bullish Takeaways Bullish analysts point to enough upside against the current trading price to justify a fresh positive view, even after trimming inputs such as discount rates and profit margins.ナラティブ更新 • Feb 05
PSTV: Upcoming CNS Trials And Diagnostics Expansion Will Drive Upside Potential
Analysts have revised their price targets for Plus Therapeutics lower, with the implied fair value estimate moving from about $9.67 to $5.50 as they incorporate updated assumptions for revenue growth, profit margins, discount rates, and a lower future P/E multiple following recent research updates. Analyst Commentary Recent research updates offer a mixed picture of how analysts are thinking about Plus Therapeutics, with some seeing attractive upside potential and others tempering expectations through lower price targets.ナラティブ更新 • Jan 22
PSTV: FDA Pivotal Trial Progress Will Drive Future Upside Potential
Narrative Update on Plus Therapeutics Analysts have adjusted their price target for Plus Therapeutics to US$1.63. The change is linked to updated assumptions for discount rate, revenue growth, profit margin, and a revised forward P/E of 49.25x, which reflect their refreshed outlook on the company’s risk and earnings potential.ナラティブ更新 • Jan 06
PSTV: Advancing Central Nervous System Cancer Trials And Grant Funding Will Drive Upside Potential
Analysts have raised their price target on Plus Therapeutics to US$1.63 per share, reflecting updated assumptions that now pair a revenue growth estimate of 96.95% with a slightly higher discount rate of 7.18%, a lower future P/E of 51.69x, and a modestly adjusted profit margin outlook of 16.24%. What's in the News Presented three clinical data updates at the WFNOS/SNO Annual Meeting in Honolulu covering multiple doses of Rhenium (186Re) Obisbemeda (Reyobiq) for leptomeningeal metastases, including rationale, design, and preliminary Cohort 1 data (Key Developments).ナラティブ更新 • Dec 15
PSTV: Expanded Brain Cancer Pipeline And Funding Will Drive Upside Potential
Narrative Update on Plus Therapeutics Analysts have raised their price target on Plus Therapeutics to approximately 83.96 from about 114.72, citing a modestly higher assumed discount rate, slightly lower long term profit margins, and somewhat stronger revenue growth expectations that together point to a more balanced, though still optimistic, valuation profile. What's in the News Presented three positive clinical data updates at the WFNOS/SNO Annual Meeting, including early ReSPECT-LM multidose trial results showing REYOBIQ was well tolerated at initial dosing levels and supporting continued dose optimization for leptomeningeal metastases patients (company announcement).ナラティブ更新 • Nov 04
PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress
Analysts have raised their fair value estimate for Plus Therapeutics from $7.88 to $9.67, citing updated revenue forecasts and improved capital structure following recent changes in financing. Analyst Commentary Analyst updates on Plus Therapeutics reflect a balanced perspective on the company’s outlook and recent financing changes.ナラティブ更新 • Sep 04
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Analysts lowered their price target for Plus Therapeutics from $8.83 to $7.88 primarily due to anticipated equity dilution from recent financing, which increased outstanding shares and warrants, though they remain positive on the company’s long-term outlook. Analyst Commentary Price target reductions reflect anticipated equity dilution following recent financing activities.分析記事 • Aug 15
We Think Plus Therapeutics (NASDAQ:PSTV) Needs To Drive Business Growth Carefully
NasdaqCM:PSTV 1 Year Share Price vs Fair Value Explore Plus Therapeutics's Fair Values from the Community and select...
新しいナラティブ • Apr 20
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Strengthened financial position and leadership could drive clinical advancements, potentially boosting future revenue and improving earnings growth.株主還元
| CNSY | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -12.4% | 0.7% | 1.8% |
| 1Y | -82.0% | 37.1% | 13.3% |
業界別リターン: CNSY過去 1 年間で37.1 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: CNSYは、過去 1 年間で13.3 % のリターンを上げたUS市場を下回りました。
価格変動
| CNSY volatility | |
|---|---|
| CNSY Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
安定した株価: CNSY 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CNSYの 週次ボラティリティ は、過去 1 年間で16%から10%に減少しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1996 | 28 | Marc Hedrick | cerenome.com |
臨床段階の製薬企業であるCerenome, Inc.は、がん患者向けの治療法の開発、製造、および商業化に注力しています。 同社の主力放射線治療候補薬は、レニウム・オビスベメダであり、これは中枢神経系がんおよび再発性膠芽腫、軟髄膜転移、小児脳腫瘍などを含むその他のがん患者を対象とした特許取得済みの放射線治療薬である。 また、レニウム-188ナノリポソーム生分解性アルギン酸マイクロスフィアを開発しており、これを動脈内注入により、原発性および転移性肝がんなどのさまざまな固形がんの治療に用いる。 さらに、がんや悪性黒色腫の患者において中枢神経系に転移した腫瘍細胞を特定するための「CNSide Test」を含む自社開発検査法の開発・商業化を行うほか、多様なデータセットを統合し、精密腫瘍学、治療法開発、臨床的意思決定を支援する実用的な知見へと変換するデータ分析および人工知能プラットフォームの開発も行っている。 同社は、以前はPlus Therapeutics, Inc.として知られていましたが、2026年8月にCerenome, Inc.に社名を変更しました。Cerenome, Inc.は1996年に設立され、テキサス州ヒューストンに本社を置いています。
Cerenome, Inc. 基礎のまとめ
| CNSY 基礎統計学 | |
|---|---|
| 時価総額 | US$15.41m |
| 収益（TTM） | -US$26.09m |
| 売上高(TTM) | US$4.20m |
3.4x
P/Sレシオ-0.6x
PER（株価収益率CNSY は割高か？
公正価値と評価分析を参照収益と収入
| CNSY 損益計算書（TTM） | |
|---|---|
| 収益 | US$4.20m |
| 売上原価 | US$12.51m |
| 売上総利益 | -US$8.30m |
| その他の費用 | US$17.78m |
| 収益 | -US$26.09m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -3.44 |
| グロス・マージン | -197.57% |
| 純利益率 | -620.70% |
| 有利子負債／自己資本比率 | 0% |
CNSY の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/21 21:07 |
| 終値 | 2026/09/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Cerenome, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Andrew D'Silva | B. Riley Securities, Inc. |
| John Savin | Edison Investment Research |